Revenue

3 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Revenue

2. Revenue

The following table is a disaggregation of revenue within each reportable segment.

	Three Months Ended December 31,
(In thousands)	2023		2022
Medical Device
Product sales	$	11,950	$	8,380
Royalties & license fees – performance coatings		8,208		7,469
License fees – SurVeil DCB		971		1,296
Research, development and other		2,416		1,873
Medical Device Revenue		23,545		19,018
In Vitro Diagnostics
Product sales		6,877		5,854
Research, development and other		130		61
In Vitro Diagnostics Revenue		7,007		5,915
Total Revenue	$	30,552	$	24,933

Contract assets totaled $9.2 million and $7.8 million as of December 31, 2023 and September 30, 2023, respectively, on the condensed consolidated balance sheets. Fluctuations in the balance of contract assets result primarily from (i) fluctuations in the sales volume of performance coating royalties and license fees earned, but not collected, at each balance sheet date due to payment timing and contractual changes in the normal course of business; and (ii) starting in fiscal 2024, sales-based profit-sharing earned, but not collected, related to a collaborative arrangement (Note 3).